vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and SPIRE INC (SR). Click either name above to swap in a different company.

SPIRE INC is the larger business by last-quarter revenue ($762.2M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.5%, a 22.0% gap on every dollar of revenue. On growth, SPIRE INC posted the faster year-over-year revenue change (13.9% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -17.8%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Spire Inc. is a regional public utility holding company based in St. Louis, Missouri, providing natural gas service through its regulated core utility operations while engaging in non-regulated activities that provide business opportunities. Its primary subsidiary Laclede Gas Company is the largest natural gas distribution utility in Missouri, serving approximately 631,000 residential, commercial and industrial customers in the City of St. Louis and ten counties in eastern Missouri. Its corpo...

RPRX vs SR — Head-to-Head

Bigger by revenue
SR
SR
1.2× larger
SR
$762.2M
$622.0M
RPRX
Growing faster (revenue YoY)
SR
SR
+9.1% gap
SR
13.9%
4.8%
RPRX
Higher net margin
RPRX
RPRX
22.0% more per $
RPRX
34.4%
12.5%
SR
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-17.8%
SR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RPRX
RPRX
SR
SR
Revenue
$622.0M
$762.2M
Net Profit
$214.2M
$95.0M
Gross Margin
55.1%
Operating Margin
62.4%
22.8%
Net Margin
34.4%
12.5%
Revenue YoY
4.8%
13.9%
Net Profit YoY
2.9%
16.9%
EPS (diluted)
$0.49
$1.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
SR
SR
Q4 25
$622.0M
$762.2M
Q3 25
$609.3M
$334.1M
Q2 25
$578.7M
$421.9M
Q1 25
$568.2M
$1.1B
Q4 24
$593.6M
$669.1M
Q3 24
$564.7M
$293.8M
Q2 24
$537.3M
$414.1M
Q1 24
$568.0M
$1.1B
Net Profit
RPRX
RPRX
SR
SR
Q4 25
$214.2M
$95.0M
Q3 25
$288.2M
$-39.8M
Q2 25
$30.2M
$20.9M
Q1 25
$238.3M
$209.3M
Q4 24
$208.2M
$81.3M
Q3 24
$544.0M
$-25.9M
Q2 24
$102.0M
$-12.6M
Q1 24
$4.8M
$204.3M
Gross Margin
RPRX
RPRX
SR
SR
Q4 25
55.1%
Q3 25
Q2 25
Q1 25
Q4 24
55.6%
Q3 24
Q2 24
Q1 24
Operating Margin
RPRX
RPRX
SR
SR
Q4 25
62.4%
22.8%
Q3 25
70.1%
-0.1%
Q2 25
36.3%
16.4%
Q1 25
94.0%
29.1%
Q4 24
60.9%
22.2%
Q3 24
6.7%
Q2 24
50.2%
7.4%
Q1 24
-13.0%
26.5%
Net Margin
RPRX
RPRX
SR
SR
Q4 25
34.4%
12.5%
Q3 25
47.3%
-11.9%
Q2 25
5.2%
5.0%
Q1 25
41.9%
19.9%
Q4 24
35.1%
12.2%
Q3 24
96.3%
-8.8%
Q2 24
19.0%
-3.0%
Q1 24
0.8%
18.1%
EPS (diluted)
RPRX
RPRX
SR
SR
Q4 25
$0.49
$1.54
Q3 25
$0.67
$-0.77
Q2 25
$0.07
$0.29
Q1 25
$0.55
$3.51
Q4 24
$0.46
$1.34
Q3 24
$1.21
$-0.63
Q2 24
$0.23
$-0.28
Q1 24
$0.01
$3.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
SR
SR
Cash + ST InvestmentsLiquidity on hand
$618.7M
$4.1M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
$3.4B
Total Assets
$19.6B
$11.9B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
SR
SR
Q4 25
$618.7M
$4.1M
Q3 25
$938.9M
$5.7M
Q2 25
$631.9M
$13.1M
Q1 25
$1.1B
$15.2M
Q4 24
$929.0M
$11.5M
Q3 24
$950.1M
$4.5M
Q2 24
$1.8B
$7.4M
Q1 24
$843.0M
$25.6M
Total Debt
RPRX
RPRX
SR
SR
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RPRX
RPRX
SR
SR
Q4 25
$9.7B
$3.4B
Q3 25
$9.6B
$3.4B
Q2 25
$9.5B
$3.5B
Q1 25
$9.8B
$3.5B
Q4 24
$10.3B
$3.3B
Q3 24
$10.3B
$3.2B
Q2 24
$9.8B
$3.3B
Q1 24
$9.9B
$3.4B
Total Assets
RPRX
RPRX
SR
SR
Q4 25
$19.6B
$11.9B
Q3 25
$19.3B
$11.6B
Q2 25
$18.3B
$11.4B
Q1 25
$17.6B
$11.3B
Q4 24
$18.2B
$11.3B
Q3 24
$18.0B
$10.9B
Q2 24
$17.7B
$10.7B
Q1 24
$16.1B
$10.7B
Debt / Equity
RPRX
RPRX
SR
SR
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
SR
SR
Operating Cash FlowLast quarter
$827.1M
$81.0M
Free Cash FlowOCF − Capex
$-121.8M
FCF MarginFCF / Revenue
-16.0%
Capex IntensityCapex / Revenue
26.6%
Cash ConversionOCF / Net Profit
3.86×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$-286.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
SR
SR
Q4 25
$827.1M
$81.0M
Q3 25
$702.6M
$-4.9M
Q2 25
$364.0M
$129.1M
Q1 25
$596.1M
$372.7M
Q4 24
$742.5M
$81.1M
Q3 24
$703.6M
$82.9M
Q2 24
$658.2M
$270.1M
Q1 24
$664.6M
$489.4M
Free Cash Flow
RPRX
RPRX
SR
SR
Q4 25
$-121.8M
Q3 25
$-227.6M
Q2 25
$-91.4M
Q1 25
$154.1M
Q4 24
$-179.5M
Q3 24
$-146.9M
Q2 24
$47.9M
Q1 24
$306.6M
FCF Margin
RPRX
RPRX
SR
SR
Q4 25
-16.0%
Q3 25
-68.1%
Q2 25
-21.7%
Q1 25
14.7%
Q4 24
-26.8%
Q3 24
-50.0%
Q2 24
11.6%
Q1 24
27.2%
Capex Intensity
RPRX
RPRX
SR
SR
Q4 25
26.6%
Q3 25
66.7%
Q2 25
52.3%
Q1 25
20.8%
Q4 24
38.9%
Q3 24
78.2%
Q2 24
53.7%
Q1 24
16.2%
Cash Conversion
RPRX
RPRX
SR
SR
Q4 25
3.86×
0.85×
Q3 25
2.44×
Q2 25
12.06×
6.18×
Q1 25
2.50×
1.78×
Q4 24
3.57×
1.00×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×
2.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

SR
SR

Residential$474.9M62%
Commercial And Industrial$148.4M19%
Gas Marketing$41.1M5%
Midstream$39.0M5%
Transportation$37.1M5%
Offsystem And Other Inventive$19.7M3%
Other Customer Revenue$4.6M1%

Related Comparisons